SecBot SecBot
SECBOTREPLAY Home › Report › ZBH

ZBH · Zimmer Biomet reported Q2 2026 adjusted EPS of $2.07, a 3.0% beat vs

ZIMMER BIOMET HOLDINGS, INC. · 8-K filed Aug 5, 2026 at 06:30 ET

At the news

BULLISHIMPACT 6/10

8-K filed Aug 5, 2026 at 06:30 ET

Zimmer Biomet reported Q2 2026 adjusted EPS of $2.07, a 3.0% beat vs. consensus of $2.01, on revenue of $2.177B (above $2.14B consensus). Revenue grew 4.8% reported (4.0% organic constant currency). The company raised full-year 2026 guidance: reported revenue growth to 3.9%-4.9% (from 2.5%-4.5%) and adjusted EPS to $8.47-$8.59 (from $8.40-$8.55), signaling confidence in H2 momentum. The beat and guidance raise are positive, but the magnitude is modest for a large-cap medtech, and the prior quarter's cross-filing context showed a similar beat with a neutral market reaction, suggesting limited upside surprise.

  • Q2 2026 net sales of $2.177B, up 4.8% reported and 4.0% organic constant currency YoY
  • Adjusted diluted EPS of $2.07, beating consensus of $2.01 by 3.0%
  • Full-year 2026 guidance raised: reported revenue growth to 3.9%-4.9% (from 2.5%-4.5%), adjusted EPS to $8.47-$8.59 (from $8.40-$8.55)
  • Operating cash flow of $447.9M and free cash flow of $308.3M in Q2

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access